Peter A. Thompson

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
New York, NY
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
By: Jennifer Fitzpatrick, Attorney-in-Fact For: Peter Thompson
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Peter A. Thompson

Form 4 holding Director, 10%+ Owner

Edgewise Therapeutics, Inc.

Security class
Common Stock
Shares / value
443,792
Estimated value
$8,933,533
Report date
03 Apr 2025
Price
$20.13
Ownership
Indirect
Form 4 holding Director

Sionna Therapeutics, Inc.

Security class
Non-Qualified Stock Option (right to buy)
Shares / value
17,340
Estimated value
Report date
17 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

PMV Pharmaceuticals, Inc.

Security class
Stock option (right to buy)
Shares / value
16,333
Estimated value
Report date
02 Jun 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Janux Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
12,500
Estimated value
Report date
14 Jun 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Decibel Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
10,000
Estimated value
Report date
17 Jun 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

ALPINE IMMUNE SCIENCES, INC.

Security class
Stock Option (Right to buy)
Shares / value
0
Estimated value
Report date
20 May 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

ALPINE IMMUNE SCIENCES, INC.

Security class
Warrant (Right to Buy)
Shares / value
0
Estimated value
Report date
11 Jan 2024
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Sionna Therapeutics, Inc.

Security class
Series B convertible preferred stock
Shares / value
0
Estimated value
Report date
10 Feb 2025
Price
Ownership
By OrbiMed Private Investments VIII, LP
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Sionna Therapeutics, Inc.

Security class
Series C convertible preferred stock
Shares / value
0
Estimated value
Report date
10 Feb 2025
Price
Ownership
By OrbiMed Private Investments VIII, LP
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Peter A. Thompson

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .